Eli Lilly

News

Insulin producers face fresh lawsuit in US over pricing

Arkansas has become the latest US state to issue a legal challenge to the big three insulin producers – Eli Lilly, Sanofi and Novo Nordisk – accusing them of deceptively driving up the pric

News

AZ bites back at rivals with new Farxiga data in heart failu...

AstraZeneca's SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it back into contention with its main rival Jardiance from Boehringer Ingelheim and Eli L

News

Lilly fires a broadside at Novo Nordisk's obesity ambitions

Denmark's Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last few years with its GLP-1 agonist drugs

News

After bempeg failure, Nektar wields the axe

Nektar has said it will cut 70% of its workforce in the wake of the comprehensive failure in trials of its immuno-oncology candidate bempegaldesleukin, which was discontinued last week.

News

Pharma group seeks digital measure standards for Alzheimer's

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the develo

News

Jardiance pulls ahead of Forxiga with heart failure approval...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has become the first drug in the class to be approved in the EU for all adults with symptomatic chronic heart failure (CHF), g

Insulin producers face fresh lawsuit in US over pricing

AZ bites back at rivals with new Farxiga data in heart failu...

Lilly fires a broadside at Novo Nordisk's obesity ambitions

After bempeg failure, Nektar wields the axe

Pharma group seeks digital measure standards for Alzheimer's

Jardiance pulls ahead of Forxiga with heart failure approval...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks